Health Care

Insider buying signals Embecta’s undervalued stock after FDA/EMA approval of its CGM sensor, showing strong safety data, low P/E, and growth potential.

4D Molecular Therapeutics insider sale: CEO David Kirn sells 1,922 shares via a 10(b)(5)(1) plan at $10.02—showing confidence while keeping long‑term stake.

Insider buying by CRL executives signals confidence in its automation‑driven growth, robust contract pipeline, and value‑based reimbursement strategy amid a volatile valuation.

Yi Sang’s modest Zimmer Biomet sale signals a tactical rebalancing of the Asia‑Pacific focus, hinting at future R&D shifts and potential market strategy changes.

Insider buys and RSUs signal confidence in Acadia’s CNS pipeline, suggesting a 2026‑2027 upside as Parkinson’s and schizophrenia trials mature.

Insight: Sarah Joanne Williams sold 265 shares of Elevance Health at RSU‑tax price, showing insider confidence while preserving long‑term ownership.

ClearPoint Neuro insider sale: Director Timothy Richards sold 5,415 shares at $12.17, a routine tax‑management move post‑RSU vesting with no market‑timing impact.

Insider sale: Robert Ortencio sold 130,000 CGH shares at $25—signals portfolio rebalancing, not a warning, but keep an eye on future block trades.

Insider buying by Ascendis Pharma’s CFO signals confidence in undervalued growth, highlighting strategic potential and long‑term value for investors.

CEO’s recent RSU purchase shows Tandem Diabetes Care’s confidence in long‑term growth, amid strong price momentum and tech‑driven diabetes solutions.